CN Patent

CN104829599B — 雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物

Assigned to SHANGHAI FOREFRONT PHARMA · Expires 2017-06-09 · 9y expired

What this patent protects

本发明涉及雷迪帕韦及其衍生物的制备方法以及用于制备雷迪帕韦的中间体化合物。具体地，本发明公开了式1化合物的制备方法以及雷迪帕韦的一系列新的制备方法。本发明的方法简便、高效，具有较好的应用前景。

USPTO Abstract

本发明涉及雷迪帕韦及其衍生物的制备方法以及用于制备雷迪帕韦的中间体化合物。具体地，本发明公开了式1化合物的制备方法以及雷迪帕韦的一系列新的制备方法。本发明的方法简便、高效，具有较好的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number: CN104829599B
Jurisdiction: CN
Classification: —
Expires: 2017-06-09
Drug substance claim: No
Drug product claim: No
Assignee: SHANGHAI FOREFRONT PHARMA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.